DPYD and neoplasm: Since the DPYD rs4294451 variant was associated with increased DPYD expression, potentially impacting the drug systemic exposure, an open question remains regarding the contribution of this polymorphism to the mechanism of resistance to 5-FU therapy and, consequently, its effect on the clinical tumor response to FL-based therapy.